南方财经3月30日电,康方生物公布2024年业绩:新药销售收入超20亿元,同比增长25%创新高。核心双抗卡度尼利、依沃西均成功被纳入国家医保目录,2025年将进入放量期。全年新药开发继续高效,包括战胜药王的依沃西获批上市在内,全年新增3款新药获批,5项新适应症审评中。2款双抗共4项III期临床获阳性结果,20项III期研究进行中。备受市场关注的依沃西首个海外III期研究(HARMONi)数据将于年...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.